Abela, A. R., Rahbarnia, A., Wood, S., et al. (2019). Adolescent exposure to Δ9-tetrahydrocannabinol delays acquisition of paired-associates learning in adulthood. Psychopharmacology, 236, 1875–1886.Google Scholar

Aldhafiri, A., Dodu, J. C., Alalawi, A., et al. (2019). Delta-9-THC exposure during zebra finch sensorimotor vocal learning increases cocaine reinforcement in adulthood. Pharmacol Biochem Behav, 185, 172764.CrossRefGoogle ScholarPubMed

Bara, A., Ferland, J. N., Rompala, G., et al. (2021). Cannabis and synaptic reprogramming of the developing brain. Nat Rev Neurosci, 22, 423–438.Google Scholar

Bruijnzeel, A. W., Knight, P., Panunzio, S., et al. (2019). Effects in rats of adolescent exposure to cannabis smoke or THC on emotional behavior and cognitive function in adulthood. Psychopharmacology, 236, 2773–2784.Google Scholar

Cha, Y. M., White, A. M., Kuhn, C. M., et al. (2006). Differential effects of delta9-THC on learning in adolescent and adult rats. Pharmacol Biochem Behav, 83, 448–455.CrossRefGoogle ScholarPubMed

Cuccurazzu, B., Zamberletti, E., Nazzaro, C., et al. (2018). Adult cellular neuroadaptations induced by adolescent THC exposure in female rats are rescued by enhancing anandamide signaling. Int J Neuropsychopharmacol, 21, 1014–1024.CrossRefGoogle ScholarPubMed

De Felice, M., Renard, J., Hudson, R., et al. (2021). l-Theanine prevents long-term affective and cognitive side effects of adolescent Δ-9-tetrahydrocannabinol exposure and blocks associated molecular and neuronal abnormalities in the mesocorticolimbic circuitry. J Neurosci, 41, 739–750.CrossRefGoogle ScholarPubMed

De Gregorio, D., Dean Conway, J., Canul, M. L., et al. (2020). Effects of chronic exposure to low doses of Δ9-tetrahydrocannabinol in adolescence and adulthood on serotonin/norepinephrine neurotransmission and emotional behaviors. Int J Neuropsychopharmacol, 23, 751–761.Google Scholar

Dow-Edwards, D., and Izenwasser, S. (2012). Pretreatment with Delta9-tetrahydrocannabinol (THC) increases cocaine-stimulated activity in adolescent but not adult male rats. Pharmacol Biochem Behav, 100, 587–591.CrossRefGoogle Scholar

Ellgren, M., Spano, S. M., and Hurd, Y. L. (2007). Adolescent cannabis exposure alters opiate intake and opioid limbic neuronal populations in adult rats. Neuropsychopharmacology, 32, 607–615.Google Scholar

EMCDDA, European Monitoring Centre for Drugs and Drug Addiction (2020). European Drug Report 2020: Trends and Developments. Luxembourg: Publications Office of the European Union.Google Scholar

Flores, Á., Maldonado, R., and Berrendero, F. (2020). THC exposure during adolescence does not modify nicotine reinforcing effects and relapse in adult male mice. Psychopharmacology, 237, 801–809.Google Scholar

Friedman, A. L., Meurice, C., and Jutkiewicz, E. M. (2019). Effects of adolescent Δ9-tetrahydrocannabinol exposure on the behavioral effects of cocaine in adult Sprague–Dawley rats. Exp Clin Psychopharmacol, 27, 326–337.Google Scholar

Gogtay, N., Giedd, J. N., Lusk, L., et al. (2004). Dynamic mapping of human cortical development during childhood through early adulthood. Proc Natl Acad Sci USA, 101, 8174–8179.CrossRefGoogle ScholarPubMed

Gomes, F. V., Guimarães, F. S., and Grace, A. A. (2014). Effects of pubertal cannabinoid administration on attentional set-shifting and dopaminergic hyper-responsivity in a developmental disruption model of schizophrenia. Int J Neuropsychopharmacol, 18, pyu018.Google Scholar

Hammond, C. J., Chaney, A., Hendrickson, B., et al. (2020). Cannabis use among U.S. adolescents in the era of marijuana legalization: A review of changing use patterns, comorbidity, and health correlates. Int Rev Psychiatry, 32, 221–234.Google Scholar

Hasin, D. S. U. S. (2018). Epidemiology of cannabis use and associated problems. Neuropsychopharmacology, 43, 195–212.Google Scholar

Higuera-Matas, A., Ucha, M., and Ambrosio, E. (2015). Long-term consequences of perinatal and adolescent cannabinoid exposure on neural and psychological processes. Neurosci Biobehav Rev, 55, 119–146.CrossRefGoogle ScholarPubMed

Hiller-Sturmhöfel, S., and Spear, L. P. (2018). Binge drinking’s effects on the developing brain-animal models. Alcohol Res, 39, 77–86.Google Scholar

Jacobs-Brichford, E., Manson, K. F., and Roitman, J. D. (2019). Effects of chronic cannabinoid exposure during adolescence on reward preference and mPFC activation in adulthood. Physiol Behav, 199, 395–404.Google Scholar

Jouroukhin, Y., Zhu, X., Shevelkin, A. V., et al. (2019). Adolescent Δ9-tetrahydrocannabinol exposure and astrocyte-specific genetic vulnerability converge on nuclear factor-κB-cyclooxygenase-2 signaling to impair memory in adulthood. Biol Psychiatry, 85, 891–903.Google Scholar

Kandel, D., and Kandel, E. (2015). The gateway hypothesis of substance abuse: Developmental, biological and societal perspectives. Acta Paediatr, 104, 130–137.CrossRefGoogle ScholarPubMed

Kasten, C. R., Zhang, Y., Boehm, S. L. II. (2017). Acute and long-term effects of Δ9-tetrahydrocannabinol on object recognition and anxiety-like activity are age- and strain-dependent in mice. Pharmacol Biochem Behav, 163, 9–19.Google Scholar

Konrad, K., Firk, C., and Uhlhaas, P. J. (2013). Brain development during adolescence: Neuroscientific insights into this developmental period. Dtsch Arztebl Int, 110, 425–431.Google Scholar

Lecca, D., Scifo, A., Pisanu, A., et al. (2020). Adolescent cannabis exposure increases heroin reinforcement in rats genetically vulnerable to addiction. Neuropharmacology, 166, 107974.Google Scholar

Levine, A., Clemenza, K., Rynn, M., et al. (2017). Evidence for the risks and consequences of adolescent cannabis exposure. J Am Acad Child Adolesc Psychiatry, 56, 214–225.CrossRefGoogle ScholarPubMed

Lopez-Rodriguez, A. B., Llorente-Berzal, A., Garcia-Segura, L. M., et al. (2014). Sex-dependent long-term effects of adolescent exposure to THC and/or MDMA on neuroinflammation and serotoninergic and cannabinoid systems in rats. Br J Pharmacol, 171, 1435–1447.Google Scholar

Melis, M., Frau, R., Kalivas, P. W., et al. (2017). New vistas on cannabis use disorder. Neuropharmacology, 124, 62–72.CrossRefGoogle ScholarPubMed

Miller, M. L., Chadwick, B., Dickstein, D. L., et al. (2019). Adolescent exposure to Δ9-tetrahydrocannabinol alters the transcriptional trajectory and dendritic architecture of prefrontal pyramidal neurons. Mol Psychiatry, 24, 588–600.Google Scholar

Molla, H. M., and Tseng, K. Y. (2020). Neural substrates underlying the negative impact of cannabinoid exposure during adolescence. Pharmacol Biochem Behav, 195, 172965.CrossRefGoogle ScholarPubMed

Murphy, M., Mills, S., Winstone, J., et al. (2017). Chronic adolescent Δ9-tetrahydrocannabinol treatment of male mice leads to long-term cognitive and behavioral dysfunction, which are prevented by concurrent cannabidiol treatment. Cannabis Cannabinoid Res, 2, 235–246.Google Scholar

Nelson, N. G., Law, W. X., Weingarten, M. J., et al. (2019). Combined ∆9-tetrahydrocannabinol and moderate alcohol administration: Effects on ingestive behaviors in adolescent male rats. Psychopharmacology, 236, 671–684.CrossRefGoogle ScholarPubMed

Nguyen, J. D., Creehan, K. M., Kerr, T. M., et al. (2020). Lasting effects of repeated ∆9-tetrahydrocannabinol vapour inhalation during adolescence in male and female rats. Br J Pharmacol, 177, 188–203.Google Scholar

Prini, P., Penna, F., Sciuccati, E., et al. (2017). Chronic Δ⁸-THC exposure differently affects histone modifications in the adolescent and adult rat brain. Int J Mol Sci, 18, 2094.CrossRefGoogle ScholarPubMed

Prini, P., Rusconi, F., Zamberletti, E., et al. (2018). Adolescent THC exposure in female rats leads to cognitive deficits through a mechanism involving chromatin modifications in the prefrontal cortex. J Psychiatry Neurosci, 43, 87–101.Google Scholar

Prini, P., Zamberletti, E., Manenti, C., et al. (2020). Neurobiological mechanisms underlying cannabis-induced memory impairment. Eur Neuropsychopharmacol, 36, 181–190.Google Scholar

Pushkin, A. N., Eugene, A. J., Lallai, V., et al. (2019). Cannabinoid and nicotine exposure during adolescence induces sex-specific effects on anxiety- and reward-related behaviors during adulthood. PLoS ONE, 14, e0211346.CrossRefGoogle ScholarPubMed

Renard, J., Rushlow, W. J., Laviolette, S. R. (2016). What can rats tell us about adolescent cannabis exposure? Insights from preclinical research. Can J Psychiatry, 61, 328–334.Google Scholar

Renard, J., Rushlow, W. J., Laviolette, S. R. (2018). Effects of adolescent THC exposure on the prefrontal GABAergic system: Implications for schizophrenia-related psychopathology. Front Psychiatry, 9, 281.CrossRefGoogle ScholarPubMed

Rodríguez, G., Neugebauer, N. M., Yao, K. L., et al. (2017). Δ9-tetrahydrocannabinol (Δ9-THC) administration after neonatal exposure to phencyclidine potentiates schizophrenia-related behavioral phenotypes in mice. Pharmacol Biochem Behav, 159, 6–11.Google Scholar

Rubino, T., and Parolaro, D. (2016). The impact of exposure to cannabinoids in adolescence: Insights from animal models. Biol Psychiatry, 79, 578–585.CrossRefGoogle ScholarPubMed

Rubino, T., Prini, P., Piscitelli, F., et al. (2015). Adolescent exposure to THC in female rats disrupts developmental changes in the prefrontal cortex. Neurobiol Dis, 73, 60–69.Google Scholar

Saravia, R., Ten-Blanco, M., Julià-Hernández, M., et al. (2019). Concomitant THC and stress adolescent exposure induces impaired fear extinction and related neurobiological changes in adulthood. Neuropharmacology, 144, 345–357.Google Scholar

Silva, L., Black, R., Michaelides, M., et al. (2016). Sex and age specific effects of delta-9-tetrahydrocannabinol during the periadolescent period in the rat: The unique susceptibility of the prepubescent animal. Neurotoxicol Teratol, 58, 88–100.CrossRefGoogle ScholarPubMed

Simone, J. J., Baumbach, J. L., and McCormick, C. M. (2018). Effects of CB1 receptor antagonism and stress exposures in adolescence on socioemotional behaviours, neuroendocrine stress responses, and expression of relevant proteins in the hippocampus and prefrontal cortex in rats. Neuropharmacology, 128, 433–447.CrossRefGoogle Scholar

Stopponi, S., Soverchia, L., Ubaldi, M., et al. (2014). Chronic THC during adolescence increases the vulnerability to stress-induced relapse to heroin seeking in adult rats. Eur Neuropsychopharmacol, 24, 1037–1045.CrossRefGoogle ScholarPubMed

Stringfield, S. J., and Torregrossa, M. M. (2021a). Disentangling the lasting effects of adolescent cannabinoid exposure. Prog Neuropsychopharmacol Biol Psychiatry, 104, 110067.CrossRefGoogle ScholarPubMed

Stringfield, S. J., and Torregrossa, M. M. (2021b). Intravenous self-administration of delta-9-THC in adolescent rats produces long-lasting alterations in behavior and receptor protein expression. Psychopharmacology, 238, 305–319.CrossRefGoogle ScholarPubMed

UNODC, United Nation Office on Drugs and Crime (2020)World Drug Report 2020 (United Nations publication, Sales No. E.20.XI.6).Google Scholar

Zamberletti, E., and Rubino, T. (2021). Impact of endocannabinoid system manipulation on neurodevelopmental processes relevant to schizophrenia. Biol Psychiatry Cogn Neurosci Neuroimaging, 6, 616–626.Google ScholarPubMed

Zamberletti, E., Beggiato, S., Steardo, L. Jr., et al. (2014). Alterations of prefrontal cortex GABAergic transmission in the complex psychotic-like phenotype induced by adolescent delta-9-tetrahydrocannabinol exposure in rats. Neurobiol Dis, 63, 35–47.CrossRefGoogle ScholarPubMed

Zamberletti, E., Gabaglio, M., Grilli, M., et al. (2016). Long-term hippocampal glutamate synapse and astrocyte dysfunctions underlying the altered phenotype induced by adolescent THC treatment in male rats. Pharmacol Res, 111, 459–470.CrossRefGoogle ScholarPubMed

Zamberletti, E., Gabaglio, M., Prini, P., et al. (2015). Cortical neuroinflammation contributes to long-term cognitive dysfunctions following adolescent delta-9-tetrahydrocannabinol treatment in female rats. Eur Neuropsychopharmacol, 25, 2404–2415.Google Scholar

Abdullaev, Y., Posner, M. I., Nunnally, R., et al. (2010). Functional MRI evidence for inefficient attentional control in adolescent chronic cannabis abuse. Behav Brain Res, 215, 45–57.Google Scholar

Albaugh, M. D., Ottino-Gonzalez, J., Sidwell, A., et al. (2021). Association of cannabis use during adolescence with neurodevelopment. JAMA Psychiatry, 78, 1–11.Google Scholar

Ashtari, M., Avants, B., Cyckowski, L., et al. (2011). Medial temporal structures and memory functions in adolescents with heavy cannabis use. J Psychiatr Res, 45, 1055–1066.Google Scholar

Baedke, J. (2013). The epigenetic landscape in the course of time: Conrad Hal Waddington’s methodological impact on the life sciences. Stud Hist Philos Biol Biomed Sci, 44, 756–773.Google Scholar

Baggio, S., Deline, S., Studer, J., et al. (2014). Routes of administration of cannabis used for nonmedical purposes and associations with patterns of drug use. J Adolesc Health, 54, 235–240.Google Scholar

Bara, A., Ferland, J. N., Rompala, G., et al. (2021). Cannabis and synaptic reprogramming of the developing brain. Nat Rev Neurosci, 22, 423–438.Google Scholar

Behan, B., Connolly, C. G., Datwani, S., et al. (2014). Response inhibition and elevated parietal-cerebellar correlations in chronic adolescent cannabis users. Neuropharmacology, 84, 131–137.CrossRefGoogle ScholarPubMed

Berghuis, P., Rajnicek, A. M., Morozov, Y. M., et al. (2007). Hardwiring the brain: Endocannabinoids shape neuronal connectivity. Science, 316, 1212–1216.Google Scholar

Calakos, K. C., Bhatt, S., Foster, D. W., et al. (2017). Mechanisms underlying sex differences in cannabis use. Curr Addict Rep, 4, 439–453.Google Scholar

Chadwick, B., Miller, M. L., and Hurd, Y. L. (2013). Cannabis use during adolescent development: Susceptibility to psychiatric illness. Front Psychiatry, 4, 129.Google Scholar

Choo, E. K., Benz, M., Zaller, N., et al. (2014). The impact of state medical marijuana legislation on adolescent marijuana use. J Adolesc Health, 55, 160–166.Google Scholar

Churchwell, J. C., Lopez-Larson, M., and Yurgelun-Todd, D. A. (2010). Altered frontal cortical volume and decision making in adolescent cannabis users. Front Psychol, 1, 225.CrossRefGoogle ScholarPubMed

De Felice, M., Renard, J., Hudson, R., et al. (2021). L-Theanine prevents long-term affective and cognitive side effects of adolescent delta-9-tetrahydrocannabinol exposure and blocks associated molecular and neuronal abnormalities in the mesocorticolimbic circuitry. J Neurosci, 41, 739–750.CrossRefGoogle ScholarPubMed

Di Forti, M., Sallis, H., Allegri, F., et al. (2014). Daily use, especially of high-potency cannabis, drives the earlier onset of psychosis in cannabis users. Schizophr Bull, 40, 1509–1517.CrossRefGoogle ScholarPubMed

Ellgren, M., Artmann, A., Tkalych, O., et al. (2008). Dynamic changes of the endogenous cannabinoid and opioid mesocorticolimbic systems during adolescence: THC effects. Eur Neuropsychopharmacol, 18, 826–834.CrossRefGoogle ScholarPubMed

Epstein, K. A., and Kumra, S. (2015). Altered cortical maturation in adolescent cannabis users with and without schizophrenia. Schizophr Res, 162, 143–152.Google Scholar

Freeman, T. P., and Winstock, A. R. (2015). Examining the profile of high-potency cannabis and its association with severity of cannabis dependence. Psychol Med, 45, 3181–3189.Google Scholar

Gilman, J. M., Kuster, J. K., Lee, S., et al. (2014). Cannabis use is quantitatively associated with nucleus accumbens and amygdala abnormalities in young adult recreational users. J Neurosci, 34, 5529–5538.Google Scholar

Hasin, D. S., Saha, T. D., Kerridge, B. T., et al. (2015). Prevalence of marijuana use disorders in the United States between 2001–2002 and 2012–2013. JAMA Psychiatry, 72, 1235–1242.Google Scholar

Hasin, D. S., Shmulewitz, D., and Sarvet, A. L. (2019). Time trends in US cannabis use and cannabis use disorders overall and by sociodemographic subgroups: A narrative review and new findings. Am J Drug Alcohol Abuse, 45, 623–643.Google Scholar

Heng, L., Beverley, J. A., Steiner, H., et al. (2011). Differential developmental trajectories for CB1 cannabinoid receptor expression in limbic/associative and sensorimotor cortical areas. Synapse, 65, 278–286.Google Scholar

Hines, L. A., Freeman, T. P., Gage, S. H., et al. (2020). Association of high-potency cannabis use with mental health and substance use in adolescence. JAMA Psychiatry, 77, 1044–1051.CrossRefGoogle ScholarPubMed

Hosseini, S., and Oremus, M. (2019). The effect of age of initiation of cannabis use on psychosis, depression, and anxiety among youth under 25 years. Can J Psychiatry, 64, 304–312.Google Scholar

Houck, J. M., Bryan, A. D., and Feldstein Ewing, S. W. (2013). Functional connectivity and cannabis use in high-risk adolescents. Am J Drug Alcohol Abuse, 39, 414–423.Google Scholar

Johnston, L. D., Miech, R. A., O’Malley, P. M., et al. (2021). Monitoring the Future National Survey Results on Drug Use 1975–2020: Overview, Key Findings on Adolescent Drug Use. Ann Arbor: Institute for Social Research, University of Michigan.Google Scholar

Knapp, A. A., Lee, D. C., Borodovsky, J. T., et al. (2019). Emerging trends in cannabis administration among adolescent cannabis users. J Adolesc Health, 64, 487–493.Google Scholar

Kumra, S., Robinson, P., Tambyraja, R., et al. (2012). Parietal lobe volume deficits in adolescents with schizophrenia and adolescents with cannabis use disorders. J Am Acad Child Adolesc Psychiatry, 51, 171–180.Google Scholar

Leos-Toro, C., Rynard, V., Murnaghan, D., et al. (2019). Trends in cannabis use over time among Canadian youth: 2004–2014. Prev Med, 118, 30–37.CrossRefGoogle ScholarPubMed

Lichenstein, S. D., Musselman, S., Shaw, D. S., et al. (2017). Nucleus accumbens functional connectivity at age 20 is associated with trajectory of adolescent cannabis use and predicts psychosocial functioning in young adulthood. Addiction, 112, 1961–1970.Google Scholar

Lopez-Larson, M. P., Bogorodzki, P., Rogowska, J., et al. (2011). Altered prefrontal and insular cortical thickness in adolescent marijuana users. Behav Brain Res, 220, 164–72.Google Scholar

Maccarrone, M., Guzman, M., Mackie, K., et al. (2014). Programming of neural cells by (endo)cannabinoids: From physiological rules to emerging therapies. Nat Rev Neurosci, 15, 786–801.Google Scholar

McLaughlin, R. J. (2018). Toward a translationally relevant preclinical model of cannabis use. Neuropsychopharmacology, 43, 213.Google Scholar

Mechoulam, R., Hanus, L. O., Pertwee, R., et al. (2014). Early phytocannabinoid chemistry to endocannabinoids and beyond. Nat Rev Neurosci, 15, 757–764.Google Scholar

Miladinovic, T., Manwell, L. A., Raaphorst, E., et al. (2020). Effects of chronic nicotine exposure on Delta(9)-tetrahydrocannabinol-induced locomotor activity and neural activation in male and female adolescent and adult rats. Pharmacol Biochem Behav, 194, 172931.Google Scholar

Miller, M. L., Chadwick, B., Dickstein, D. L., et al. (2019). Adolescent exposure to Delta(9)-tetrahydrocannabinol alters the transcriptional trajectory and dendritic architecture of prefrontal pyramidal neurons. Mol Psychiatry, 24, 588–600.Google Scholar

Moore, C. F., Davis, C. M., Harvey, E. L., et al. (2021). Appetitive, antinociceptive, and hypothermic effects of vaped and injected Delta-9-tetrahydrocannabinol (THC) in rats: Exposure and dose-effect comparisons by strain and sex. Pharmacol Biochem Behav, 202, 173116.Google Scholar

Orr, C., Morioka, R., Behan, B., et al. (2013). Altered resting-state connectivity in adolescent cannabis users. Am J Drug Alcohol Abuse, 39, 372–381.Google Scholar

Orr, C., Spechler, P., Cao, Z., et al. (2019). Grey matter volume differences associated with extremely low levels of cannabis use in adolescence. J Neurosci, 39, 1817–1827.Google Scholar

Padula, C. B., Schweinsburg, A. D., and Tapert, S. F. (2007). Spatial working memory performance and fMRI activation interaction in abstinent adolescent marijuana users. Psychol Addict Behav, 21, 478–487.Google Scholar

Peters, E. N., Bae, D., Barrington-Trimis, J. L., et al. (2018). Prevalence and sociodemographic correlates of adolescent use and polyuse of combustible, vaporized, and edible cannabis products. JAMA Netw Open, 1, e182765.Google Scholar

Pope, H. G., Gruber, A. J., Hudson, J. I., et al. (2003). Early-onset cannabis use and cognitive deficits: What is the nature of the association? Drug Alcohol Depend, 69, 303–310.Google Scholar

Rais, M., Van Haren, N. E., Cahn, W., et al. (2010). Cannabis use and progressive cortical thickness loss in areas rich in CB1 receptors during the first five years of schizophrenia. Eur Neuropsychopharmacol, 20, 855–865.Google Scholar

Renard, J., Rushlow, W. J., and Laviolette, S. R. (2016). What can rats tell us about adolescent cannabis exposure? Insights from preclinical research. Can J Psychiatry, 61, 328–334.CrossRefGoogle ScholarPubMed

Renard, J., Szkudlarek, H. J., Kramar, C. P., et al. (2017). Adolescent THC exposure causes enduring prefrontal cortical disruption of GABAergic inhibition and dysregulation of sub-cortical dopamine function. Sci Rep, 7, 11420.CrossRefGoogle ScholarPubMed

Rodriguez de Fonseca, F., Ramos, J. A., Bonnin, A., et al. (1993). Presence of cannabinoid binding sites in the brain from early postnatal ages. Neuroreport, 4, 135–138.Google Scholar

Rubino, T., and Parolaro, D. (2008). Long lasting consequences of cannabis exposure in adolescence. Mol Cell Endocrinol, 286, S108–113.Google Scholar

Ruiz, C. M., Torrens, A., Castillo, E., et al. (2021a). Pharmacokinetic, behavioral, and brain activity effects of Delta(9)-tetrahydrocannabinol in adolescent male and female rats. Neuropsychopharmacology, 46, 959–969.Google Scholar

Ruiz, C. M., Torrens, A., Lallai, V., et al. (2021b). Pharmacokinetic and pharmacodynamic properties of aerosolized (‘vaped’) THC in adolescent male and female rats. Psychopharmacology (Berl), 238, 3595–3605.Google Scholar

Saravia, R., Ten-Blanco, M., Julia-Hernandez, M., et al. (2019). Concomitant THC and stress adolescent exposure induces impaired fear extinction and related neurobiological changes in adulthood. Neuropharmacology, 144, 345–357.Google Scholar

Schulenberg, J. E., Merline, A. C., Johnston, L. D., et al. (2005). Trajectories of marijuana use during the transition to adulthood: The big picture based on national panel data. J Drug Issues, 35, 255–279.CrossRefGoogle ScholarPubMed

Schweinsburg, A. D., Schweinsburg, B. C., Medina, K. L., et al. (2010). The influence of recency of use on fMRI response during spatial working memory in adolescent marijuana users. J Psychoactive Drugs, 42, 401–412.Google Scholar

Scott, J. C., Rosen, A. F. G., Moore, T. M., et al. (2019). Cannabis use in youth is associated with limited alterations in brain structure. Neuropsychopharmacology, 44, 1362–1369.CrossRefGoogle ScholarPubMed

Spechler, P. A., Orr, C. A., Chaarani, B., et al. (2015). Cannabis use in early adolescence: Evidence of amygdala hypersensitivity to signals of threat. Dev Cogn Neurosci, 16, 63–70.Google Scholar

Tapert, S. F., Schweinsburg, A. D., Drummond, S. P., et al. (2007) Functional MRI of inhibitory processing in abstinent adolescent marijuana users. Psychopharmacology (Berl), 194, 173–183.Google Scholar

Taylor, M., Collin, S. M., Munafo, M. R., et al. (2017). Patterns of cannabis use during adolescence and their association with harmful substance use behaviour: Findings from a UK birth cohort. J Epidemiol Community Health, 71, 764–770.Google Scholar

Tervo-Clemmens, B., Simmonds, D., Calabro, F. J., et al. (2018). Early cannabis use and neurocognitive risk: A prospective functional neuroimaging study. Biol Psychiatry Cogn Neurosci Neuroimaging, 3, 713–725.Google Scholar

Van Speybroeck, L. (2002). From epigenesis to epigenetics: The case of C. H. Waddington. Ann NY Acad Sci, 981, 61–81.Google Scholar

Weiland, B. J., Thayer, R. E., Depue, B. E., et al. (2015). Daily marijuana use is not associated with brain morphometric measures in adolescents or adults. J Neurosci, 35, 1505–1512.Google Scholar

Yu, T., Jia, T., Zhu, L., et al. (2020). Cannabis-associated psychotic-like experiences are mediated by developmental changes in the parahippocampal gyrus. J Am Acad Child Adolesc Psychiatry, 59, 642–649.Google Scholar

Adam, K. C. S., Doss, M. K., Pabon, E., et al. (2020). Δ9-tetrahydrocannabinol (THC) impairs visual working memory performance: A randomized crossover trial. Neuropsychopharmacology, 45, 1807–1816.Google Scholar

Alcorn, J. L. 3rd, Marks, K. R., Stoops, W. W., et al. (2019). Attentional bias to cannabis cues in cannabis users but not cocaine users. Addict Behav, 88, 129–136.Google Scholar

Ballard, M. E., Gallo, D. A., and De Wit, H. (2012). Psychoactive drugs and false memory: Comparison of dextroamphetamine and δ-9-tetrahydrocannabinol on false recognition. Psychopharmacology (Berl), 219, 15–24.Google Scholar

Barfi, E., Tehrani, A. M., Mohammadpanah, M., et al. (2021). The role of tetrahydrocannabinol in inducing disrupted signaling cascades, hippocampal atrophy and memory defects. J Chem Neuroanat, 113, 101943.Google Scholar

Batalla, A., Crippa, J. A., Busatto, G. F., et al. (2014). Neuroimaging studies of acute effects of THC and CBD in humans and animals: A systematic review. Curr Pharm Des, 20, 2168–2185.Google Scholar

Battistella, G., Fornari, E., Annoni, J.-M., et al. (2014). Long-term effects of cannabis on brain structure. Neuropsychopharmacology, 39, 2041–2048.Google Scholar

Bedi, G., Cooper, Z. D., & Haney, M. (2013). Subjective, cognitive and cardiovascular dose–effect profile of nabilone and dronabinol in marijuana smokers. Addict Biol, 18, 872–881.Google Scholar

Bhattacharyya, S., Atakan, Z., Martin-Santos, R., et al. (2015). Impairment of inhibitory control processing related to acute psychotomimetic effects of cannabis. Eur Neuropsychopharmacol, 25, 26–37.Google Scholar

Bhattacharyya, S., Egerton, A., Kim, E., et al. (2017). Acute induction of anxiety in humans by delta-9-tetrahydrocannabinol related to amygdalar cannabinoid-1 (CB1) receptors. Sci Rep, 7, 15025.CrossRefGoogle ScholarPubMed

Blest-Hopley, G., O’Neill, A., Wilson, R., et al. (2021). Disrupted parahippocampal and midbrain function underlie slower verbal learning in adolescent-onset regular cannabis use. Psychopharmacology (Berl), 238, 1315–1331.Google Scholar

Bloomfield, M. A. P., Green, S. F., Hindocha, C., et al. (2020). The effects of acute cannabidiol on cerebral blood flow and its relationship to memory: An arterial spin labelling magnetic resonance imaging study. J Psychopharmacol, 34, 981–989.Google Scholar

Bonn-Miller, M. O., Elsohly, M. A., Loflin, M. J. E., et al. (2018). Cannabis and cannabinoid drug development: Evaluating botanical versus single molecule approaches. Int Rev Psychiatry, 30, 277–284.Google Scholar

Borgan, F., Beck, K., Butler, E., et al. (2019). The effects of cannabinoid 1 receptor compounds on memory: A meta-analysis and systematic review across species. Psychopharmacology (Berl), 236, 3257–3270.Google Scholar

Bosker, W. M., Karschner, E. L., Lee, D., et al. (2013). Psychomotor function in chronic daily cannabis smokers during sustained abstinence. PLoS ONE, 8, e53127.Google Scholar

Bossong, M. G., Jansma, J. M., Van Hell, H. H., et al. (2012). Effects of δ9-tetrahydrocannabinol on human working memory function. Biol Psychiatry, 71, 693–699.Google Scholar

Bossong, M. G., Mehta, M. A., Van Berckel, B. N., et al. (2015). Further human evidence for striatal dopamine release induced by administration of ∆9-tetrahydrocannabinol (THC): Selectivity to limbic striatum. Psychopharmacology (Berl), 232, 2723–2729.Google Scholar

Bourque, J., and Potvin, S. (2021). Cannabis and cognitive functioning: From acute to residual effects, from randomized controlled trials to prospective designs. Front Psychiatry, 12, 919.Google Scholar

Broyd, S.J., Greenwood, L.-M., Van Hell, H. H., et al. (2016a). Mismatch negativity and P50 sensory gating in abstinent former cannabis users. Neural Plast, 2016, 6526437.Google Scholar

Broyd, S.J., Van Hell, H. H., Yucel, M., et al. (2016b). Acute and chronic effects of cannabinoids on human cognition: A systematic review. Biol Psychiatry, 79, 557–567.Google Scholar

Castellanos-Ryan, N., Pingault, J.-B., Parent, S., et al. (2017). Adolescent cannabis use, change in neurocognitive function, and high-school graduation: A longitudinal study from early adolescence to young adulthood. Dev Psychopathol, 29, 1253–1266.Google Scholar

Ceccarini, J., Kuepper, R., Kemels, D., et al. (2015). [18f]mk-9470 pet measurement of cannabinoid CB1 receptor availability in chronic cannabis users. Addict Biol, 20, 357–367.Google Scholar

Cengel, H. Y., Bozkurt, M., Evren, C., et al. (2018). Evaluation of cognitive functions in individuals with synthetic cannabinoid use disorder and comparison to individuals with cannabis use disorder. Psychiatry Res, 262, 46–54.Google Scholar

Chandra, S., Radwan, M. M., Majumdar, C. G., et al. (2019). New trends in cannabis potency in USA and Europe during the last decade (2008–2017). Eur Arch Psychiatry Clin Neurosci, 269, 5–15.Google Scholar

Chye, Y., Kirkham, R., Lorenzetti, V., et al. (2021). Cannabis, cannabinoids, and brain morphology: A review of the evidence. Biol Psychiatry Cogn Neurosci Neuroimaging, 6, 627–635.Google Scholar

Chye, Y., Lorenzetti, V., Suo, C., et al. (2019). Alteration to hippocampal volume and shape confined to cannabis dependence: A multi-site study. Addict Biol, 24, 822–834.Google Scholar

Colizzi, M., and Bhattacharyya, S. (2017). Does cannabis composition matter? Differential effects of delta-9-tetrahydrocannabinol and cannabidiol on human cognition. Curr Addic Rep, 4, 62–74.Google Scholar

Colizzi, M., and Bhattacharyya, S. (2018). Cannabis use and the development of tolerance: A systematic review of human evidence. Neurosci Biobehav Rev, 93, 1–25.Google Scholar

Colizzi, M., Fazio, L., Ferranti, L., et al. (2015). Functional genetic variation of the cannabinoid receptor 1 and cannabis use interact on prefrontal connectivity and related working memory behavior. Neuropsychopharmacology, 40, 640–649.Google Scholar

Colizzi, M., McGuire, P., Giampietro, V., et al. (2018). Previous cannabis exposure modulates the acute effects of delta-9-tetrahydrocannabinol on attentional salience and fear processing. Exp Clin Psychopharmacol, 26, 582–598.Google Scholar

Colizzi, M., Weltens, N., Mcguire, P., et al. (2020). Delta-9-tetrahydrocannabinol increases striatal glutamate levels in healthy individuals: Implications for psychosis. Mol Psychiatry, 25, 3231–3240.Google Scholar

Cousijn, J., Goudriaan, A. E., Ridderinkhof, K. R., et al. (2013). Neural responses associated with cue-reactivity in frequent cannabis users. Addict Biol, 18, 570–580.Google Scholar

Cousijn, J., Wiers, R. W., Ridderinkhof, K. R., et al. (2014). Effect of baseline cannabis use and working-memory network function on changes in cannabis use in heavy cannabis users: A prospective FMRI study. Hum Brain Mapp, 35, 2470–2482.Google Scholar

Crane, N. A., Schuster, R. M., and Gonzalez, R. (2013). Preliminary evidence for a sex-specific relationship between amount of cannabis use and neurocognitive performance in young adult cannabis users. J Int Neuropsychol Soc, 19, 1009–1015.Google Scholar

Curran, T., Devillez, H., Yorkwilliams, S. L., et al. (2020). Acute effects of naturalistic THC vs. CBD use on recognition memory: A preliminary study. J Cannabis Res, 2, 28.CrossRefGoogle ScholarPubMed

Cuttler, C., Mclaughlin, R. J., and Graf, P. (2012). Mechanisms underlying the link between cannabis use and prospective memory. PLoS ONE, 7, e36820.Google Scholar

D’Souza, D. C., Cortes-Briones, J. A., Ranganathan, M., et al. (2016). Rapid changes in CB1 receptor availability in cannabis dependent males after abstinence from cannabis. Biol Psychiatry Cogn Neurosci Neuroimaging, 1, 60–67.Google Scholar

Day, A. M., Metrik, J., Spillane, N. S., et al. (2013). Working memory and impulsivity predict marijuana-related problems among frequent users. Drug Alcohol Depend, 131, 171–174.CrossRefGoogle ScholarPubMed

Desrosiers, N. A., Himes, S. K., Scheidweiler, K. B., et al. (2014). Phase I and II cannabinoid disposition in blood and plasma of occasional and frequent smokers following controlled smoked cannabis. Clin Chem, 60, 631–643.Google Scholar

Dinis-Oliveira, R. J. (2016). Metabolomics of δ9-tetrahydrocannabinol: Implications in toxicity. Drug Metab Rev, 48, 80–87.Google Scholar

Doss, M. K., Weafer, J., Gallo, D. A., et al. (2018). Δ9-tetrahydrocannabinol at retrieval drives false recollection of neutral and emotional memories. Biol Psychiatry, 84, 743–750.Google Scholar

Duperrouzel, J. C., Hawes, S. W., Lopez-Quintero, C., et al. (2019). Adolescent cannabis use and its associations with decision-making and episodic memory: Preliminary results from a longitudinal study. Neuropsychology, 33, 701–710.Google Scholar

ElSohly, M. A., Mehmedic, Z., Foster, S., et al. (2016). Changes in cannabis potency over the last 2 decades (1995–2014): Analysis of current data in the united states. Biol Psychiatry, 79, 613–619.Google Scholar

Englund, A., Atakan, Z., Kralj, A., et al. (2015). The effect of five day dosing with THCV on THC-induced cognitive, psychological and physiological effects in healthy male human volunteers: A placebo-controlled, double-blind, crossover pilot trial. J Psychopharmacol, 30, 140–151.Google Scholar

Englund, A., Freeman, T. P., Murray, R. M., et al. (2017). Can we make cannabis safer? Lancet Psychiatry, 4, 643–648.Google Scholar

Englund, A., Morrison, P. D., Nottage, J., et al. (2013). Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment. J Psychopharmacol (Oxford), 27, 19–27.Google Scholar

European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). (2015). European Drug Report 2015: Trends and Developments. Luxembourg: Publications Office of the European Union.Google Scholar

Fan, N., Yang, H., Zhang, J., et al. (2010). Reduced expression of glutamate receptors and phosphorylation of creb are responsible for in vivo δ9-THC exposure-impaired hippocampal synaptic plasticity. J Neurochem, 112, 691–702.Google Scholar

Filbey, F. M., Aslan, S., Calhoun, V. D., et al. (2014). Long-term effects of marijuana use on the brain. PNAS, 111, 16913.Google Scholar

Fishbein, M., Gov, S., Assaf, F., et al. (2012). Long-term behavioral and biochemical effects of an ultra-low dose of δ9-tetrahydrocannabinol (THC): Neuroprotection and erk signaling. Exp Brain Res, 221, 437–448.Google Scholar

Fontes, M. A., Bolla, K. I., Cunha, P. J., et al. (2018). Cannabis use before age 15 and subsequent executive functioning. Br J Psychiatry, 198, 442–447.Google Scholar

Freeman, A. M., Petrilli, K., Lees, R., et al. (2019). How does cannabidiol (CBD) influence the acute effects of delta-9-tetrahydrocannabinol (THC) in humans? A systematic review. Neurosci Biobehav Rev, 107, 696–712.Google Scholar

Freeman, T. P., Craft, S., Wilson, J., et al. (2021). Changes in delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) concentrations in cannabis over time: Systematic review and meta-analysis. Addiction, 116, 1000–1010.Google Scholar

Freeman, T. P., Hindocha, C., Green, S. F., et al. (2019). Medicinal use of cannabis based products and cannabinoids. BMJ, 365, l1141.Google Scholar

Freeman, T. P., Morgan, C. J., Hindocha, C., et al. (2014). Just say ‘know’: How do cannabinoid concentrations influence users’ estimates of cannabis potency and the amount they roll in joints? Addiction, 109, 1686–1694.Google Scholar

Fried, P. A., Watkinson, B., and Gray, R. (2005). Neurocognitive consequences of marihuana: A comparison with pre-drug performance. Neurotoxicol Teratol, 27, 231–239.Google Scholar

Frolli, A., Ricci, M. C., Cavallaro, A., et al. (2021). Cognitive development and cannabis use in adolescents. Behav Sci (Basel), 11, 37.Google Scholar

Gajewski, P. D., Hanisch, E., Falkenstein, M., et al. (2018). What does the N-back task measure as we get older? Relations between working-memory measures and other cognitive functions across the lifespan. Front Psychol, 9, 2208.Google Scholar

Ganzer, F., Bröning, S., Kraft, S., et al. (2016). Weighing the evidence: A systematic review on long-term neurocognitive effects of cannabis use in abstinent adolescents and adults. Neuropsychol Rev, 26, 186–222.Google Scholar

Gessa, G. L., Casu, M. A., Carta, G., et al. (1998). Cannabinoids decrease acetylcholine release in the medial-prefrontal cortex and hippocampus, reversal by sr 141716a. Eur J Pharmacol, 355, 119–124.Google Scholar

van de Giessen, E., Weinstein, J. J., Cassidy, C. M., et al. (2017). Deficits in striatal dopamine release in cannabis dependence. Mol Psychiatry, 22, 68–75.Google Scholar

Gonzalez, R., Schuster, R. M., Mermelstein, R. J., et al. (2012). Performance of young adult cannabis users on neurocognitive measures of impulsive behavior and their relationship to symptoms of cannabis use disorders. J Clin Exp Neuropsychol, 34, 962–976.Google Scholar

Gorey, C., Kuhns, L., Smaragdi, E., et al. (2019). Age-related differences in the impact of cannabis use on the brain and cognition: A systematic review. Eur Arch Psychiatry Clin Neurosci, 269, 37–58.Google Scholar

Government of Canada (GOC). (2019). Canadian tobacco, alcohol and drugs survey (CTADS): Summary of results for 2017. Available at: www.canada.ca/en/health-canada/services/canadian-tobacco-alcohol-drugs-survey/2017-summary.html (Last accessed 9 April 2021).Google Scholar

Grant, J. E., Chamberlain, S. R., Schreiber, L., et al. (2012). Neuropsychological deficits associated with cannabis use in young adults. Drug Alcohol Depend, 121, 159–162.Google Scholar

Griffith-Lendering, M. F. H., Huijbregts, S. C. J., Vollebergh, W. A. M., et al. (2012). Motivational and cognitive inhibitory control in recreational cannabis users. J Clin Exp Neuropsychol, 34, 688–697.Google Scholar

Gunasekera, B., Diederen, K., and Bhattacharyya, S. (2022). Cannabinoids, reward processing, and psychosis. Psychopharmacology (Berl), 239, 1157–1177.Google Scholar

Hall, W., Hoch, E., and Lorenzetti, V. (2019). Cannabis use and mental health: Risks and benefits. Eur Arch Psychiatry Clin Neurosci, 269, 1–3.Google Scholar

Herzig, D. A., Nutt, D. J., and Mohr, C. (2014). Alcohol and relatively pure cannabis use, but not schizotypy, are associated with cognitive attenuations. Front Psychiatry, 5, 133.Google Scholar

Hill, S. Y., Sharma, V., and Jones, B. L. (2016). Lifetime use of cannabis from longitudinal assessments, cannabinoid receptor (CNR1) variation, and reduced volume of the right anterior cingulate. Psychiatry Res Neuroimaging, 255, 24–34.Google Scholar

Hirvonen, J. (2015). In vivo imaging of the cannabinoid CB1 receptor with positron emission tomography. Clin Pharmacol Ther, 97, 565–567.Google Scholar

Hirvonen, J., Goodwin, R. S., Li, C. T., et al. (2012). Reversible and regionally selective downregulation of brain cannabinoid CB1 receptors in chronic daily cannabis smokers. Mol Psychiatry, 17, 642–649.Google Scholar

Hooper, S. R., Woolley, D., and De Bellis, M. D. (2014). Intellectual, neurocognitive, and academic achievement in abstinent adolescents with cannabis use disorder. Psychopharmacology (Berl), 231, 1467–1477.Google Scholar

Hughes, A., Lipari, R. N., and Williams, M. R. (2016). Marijuana use and perceived risk of harm from marijuana use varies within and across states. In: The CBHSQ Report. Rockville, MD: Substance Abuse and Mental Health Services Administration (US). Available at: www.ncbi.nlm.nih.gov/books/NBK396156/. Last accessed 30 October 2022.Google Scholar

Hurd, Y. L., Manzoni, O. J., Pletnikov, M. V., et al. (2019). Cannabis and the developing brain: Insights into its long-lasting effects. J Neurosci, 39, 8250.Google Scholar

Jacobs, D. S., Kohut, S. J., Jiang, S., et al. (2016). Acute and chronic effects of cannabidiol on δ⁹-tetrahydrocannabinol (δ⁹-THC)-induced disruption in stop signal task performance. Exp Clin Psychopharmacol, 24, 320–330.Google Scholar

Kaczkurkin, A. N., Raznahan, A., and Satterthwaite, T. D. (2019). Sex differences in the developing brain: Insights from multimodal neuroimaging. Neuropsychopharmacology, 44, 71–85.Google Scholar

Khan, R., Naveed, S., Mian, N., et al. (2020). The therapeutic role of cannabidiol in mental health: A systematic review. J Cannabis Res, 2, 2.Google Scholar

Kloft, L., Otgaar, H., Blokland, A., et al. (2020). Cannabis increases susceptibility to false memory. PNAS, 117, 4585.Google Scholar

Koob, G. F. D., and Volkow, N. D. M. D. (2016). Neurobiology of addiction: A neurocircuitry analysis. Lancet Psychiatry, 3, 760–773.Google Scholar

Kroon, E., Kuhns, L., and Cousijn, J. (2021). The short-term and long-term effects of cannabis on cognition: Recent advances in the field. Curr Opin Psychol, 38, 49–55.Google Scholar

Krzyzanowski, D. J., and Purdon, S. E. (2020). Duration of abstinence from cannabis is positively associated with verbal learning performance: A systematic review and meta-analysis. Neuropsychology, 34, 359–372.Google Scholar

Larsen, B., and Luna, B. (2018). Adolescence as a neurobiological critical period for the development of higher-order cognition. Neurosci Biobehav Rev, 94, 179–195.Google Scholar

Lisdahl, K. M., and Price, J. S. (2012). Increased marijuana use and gender predict poorer cognitive functioning in adolescents and emerging adults. J Int Neuropsychol Soc, 18, 678–688.Google Scholar

Lorenzetti, V., Chye, Y., Silva, P., et al. (2019). Does regular cannabis use affect neuroanatomy? An updated systematic review and meta-analysis of structural neuroimaging studies. Eur Arch Psychiatry Clin Neurosci, 269, 59–71.Google Scholar

Lorenzetti, V., Chye, Y., Suo, C., et al. (2020a). Neuroanatomical alterations in people with high and low cannabis dependence. Aust NZ J Psychiatry, 54, 68–75.Google Scholar

Lorenzetti, V., Hoch, E., and Hall, W. (2020b). Adolescent cannabis use, cognition, brain health and educational outcomes: A review of the evidence. Eur Neuropsychopharmacol, 36, 169–180.Google Scholar

Lorenzetti, V., Takagi, M., Van Dalen, Y., et al. (2021). Investigating the residual effects of chronic cannabis use and abstinence on verbal and visuospatial learning. Front Psychiatry, 12, 663701.Google Scholar

Lovell, M. E., Akhurst, J., Padgett, C., et al. (2020). Cognitive outcomes associated with long-term, regular, recreational cannabis use in adults: A meta-analysis. Exp Clin Psychopharmacol, 28, 471–494.Google Scholar

Lubman, D. I., Cheetham, A., and Yücel, M. (2015). Cannabis and adolescent brain development. Pharmacol Ther, 148, 1–16.Google Scholar

Ma, L., Steinberg, J. L., Bjork, J. M., et al. (2018). Fronto-striatal effective connectivity of working memory in adults with cannabis use disorder. Psychiatry Res Neuroimaging, 278, 21–34.Google Scholar

Mason, N. L., Theunissen, E. L., Hutten, N. R. P. W., et al. (2021). Reduced responsiveness of the reward system is associated with tolerance to cannabis impairment in chronic users. Addict Biol, 26, e12870.Google Scholar

Matheson, J., and Le Foll, B. (2020). Cannabis legalization and acute harm from high potency cannabis products: A narrative review and recommendations for public health. Front Psychiatry, 11, 1017.Google Scholar

McCartney, D., Arkell, T. R., Irwin, C., et al. (2021). Determining the magnitude and duration of acute δ(9)-tetrahydrocannabinol (δ(9)-THC)-induced driving and cognitive impairment: A systematic and meta-analytic review. Neurosci Biobehav Rev, 126, 175–193.Google Scholar

Medina, K. L., Hanson, K. L., Schweinsburg, A. D., et al. (2007). Neuropsychological functioning in adolescent marijuana users: Subtle deficits detectable after a month of abstinence. J Int Neuropsychol Soc, 13, 807–820.Google Scholar

Meier, M. H., Caspi, A., Ambler, A., et al. (2012). Persistent cannabis users show neuropsychological decline from childhood to midlife. PNAS, 109, E2657–E2664.Google Scholar

Metrik, J., Kahler, C. W., Reynolds, B., et al. (2012). Balanced placebo design with marijuana: Pharmacological and expectancy effects on impulsivity and risk taking. Psychopharmacology (Berl), 223, 489–499.Google Scholar

Mizrahi, R., Watts, J. J., and Tseng, K. Y. (2017). Mechanisms contributing to cognitive deficits in cannabis users. Neuropharmacology, 124, 84–88.Google Scholar

Moeller, S. J., Bederson, L., Alia-Klein, N., et al. (2016). Neuroscience of inhibition for addiction medicine: From prediction of initiation to prediction of relapse. Prog Brain Res, 223, 165–188.Google Scholar

Moreno, M., Estevez, A. F., Zaldivar, F., et al. (2012). Impulsivity differences in recreational cannabis users and binge drinkers in a university population. Drug Alcohol Depend, 124, 355–362.Google Scholar

Morgan, C. J. A., Freeman, T. P., Hindocha, C., et al. (2018). Individual and combined effects of acute delta-9-tetrahydrocannabinol and cannabidiol on psychotomimetic symptoms and memory function. Transl Psychiatry, 8, 181.Google Scholar

Morgan, C. J. A., Freeman, T. P., Schafer, G. L., et al. (2010). Cannabidiol attenuates the appetitive effects of δ9-tetrahydrocannabinol in humans smoking their chosen cannabis. Neuropsychopharmacology, 35, 1879–1885.Google Scholar

Morin, J.-F. G., Afzali, M. H., Bourque, J., et al. (2018). A population-based analysis of the relationship between substance use and adolescent cognitive development. Am J Psychiatry, 176, 98–106.Google Scholar

Muetzel, R. L., Marjańska, M., Collins, P. F., et al. (2013). In vivo 1h magnetic resonance spectroscopy in young-adult daily marijuana users. Neuroimage Clin, 2, 581–589.Google Scholar

Murray, R. M., Englund, A., Abi-Dargham, A., et al. (2017). Cannabis-associated psychosis: Neural substrate and clinical impact. Neuropharmacology, 124, 89–104.Google Scholar

Nader, D. A., and Sanchez, Z. M. (2018). Effects of regular cannabis use on neurocognition, brain structure, and function: A systematic review of findings in adults. Am J Drug Alcohol Abuse, 44, 4–18.Google Scholar

Niesink, R. J., and van Laar, M. W. (2013). Does cannabidiol protect against adverse psychological effects of THC? Front Psychiatry, 4, 130.Google Scholar

O’Neill, A., Bachi, B., and Bhattacharyya, S. (2020). Attentional bias towards cannabis cues in cannabis users: A systematic review and meta-analysis. Drug Alcohol Depend, 206, 107719.Google Scholar

Oomen, P. P., Van Hell, H. H., and Bossong, M. G. (2018). The acute effects of cannabis on human executive function. Behav Pharmacol, 29, 605–616.Google Scholar

Ortega-Mora, I. E., Caballero-Sánchez, U., Román-López, T. V., et al. (2021). The alerting and orienting systems of attention are modified by cannabis dependence. J Int Neuropsychol Soc, 27, 520–532.Google Scholar

Owens, M. M., Mcnally, S., Petker, T., et al. (2019). Urinary tetrahydrocannabinol is associated with poorer working memory performance and alterations in associated brain activity. Neuropsychopharmacology, 44, 613–619.Google Scholar

Paige, K. J., and Colder, C. R. (2020). Long-term effects of early adolescent marijuana use on attentional and inhibitory control. J Stud Alcohol Drugs, 81, 164–172.Google Scholar

Petker, T., Owens, M. M., Amlung, M. T., et al. (2019). Cannabis involvement and neuropsychological performance: Findings from the human connectome project. J Psychiatry Neurosci, 44, 414–422.Google Scholar

Plitman, E., Nakajima, S., De La Fuente-Sandoval, C., et al. (2014). Glutamate-mediated excitotoxicity in schizophrenia: A review. Eur Neuropsychopharmacol, 24, 1591–1605.Google Scholar

Potter, D. J., Hammond, K., Tuffnell, S., et al. (2018). Potency of δ(9)-tetrahydrocannabinol and other cannabinoids in cannabis in England in 2016: Implications for public health and pharmacology. Drug Testing Anal, 10, 628–635.Google Scholar

Prescot, A. P., Renshaw, P. F., and Yurgelun-Todd, D. A. (2013). γ-amino butyric acid and glutamate abnormalities in adolescent chronic marijuana smokers. Drug Alcohol Depend, 129, 232–239.Google Scholar

Prini, P., Zamberletti, E., Manenti, C., et al. (2020). Neurobiological mechanisms underlying cannabis-induced memory impairment. Eur Neuropsychopharmacol, 36, 181–190.Google Scholar

Ramaekers, J. G., Mason, N. L., Kloft, L., et al. (2021). The why behind the high: Determinants of neurocognition during acute cannabis exposure. Nat Rev Neurosci, 22, 439–454.Google Scholar

Ramaekers, J. G., Mason, N. L., and Theunissen, E. L. (2020). Blunted highs: Pharmacodynamic and behavioral models of cannabis tolerance. Eur Neuropsychopharmacol, 36, 191–205.Google Scholar

Ramaekers, J. G., Van Wel, J. H., Spronk, D. B., et al. (2016). Cannabis and tolerance: Acute drug impairment as a function of cannabis use history. Sci Rep, 6, 26843–26843.Google Scholar

Ranganathan, M., Radhakrishnan, R., Addy, P. H., et al. (2017). Tetrahydrocannabinol (THC) impairs encoding but not retrieval of verbal information. Prog Neuropsychopharmacol Biol Psychiatry, 79, 176–183.Google Scholar

Rangel-Pacheco, A., Lew, B. J., Schantell, M. D., et al. (2021). Altered fronto-occipital connectivity during visual selective attention in regular cannabis users. Psychopharmacology (Berl), 238, 1351–1361.Google Scholar

Riba, J., Valle, M., Sampedro, F., et al. (2015). Telling true from false: Cannabis users show increased susceptibility to false memories. Mol Psychiatry, 20, 772–777.Google Scholar

Roten, A., Baker, N. L., and Gray, K. M. (2015). Cognitive performance in a placebo-controlled pharmacotherapy trial for youth with marijuana dependence. Addict Behav, 45, 119–123.Google Scholar

Sagar, K. A., and Gruber, S. A. (2018). Marijuana matters: Reviewing the impact of marijuana on cognition, brain structure and function, & exploring policy implications and barriers to research. Int Rev Psychiatry, 30, 251–267.Google Scholar

Sami, M. B., Rabiner, E. A., and Bhattacharyya, S. (2015). Does cannabis affect dopaminergic signaling in the human brain? A systematic review of evidence to date. Eur Neuropsychopharmacol, 25, 1201–1224.Google Scholar

Schlienz, N. J., Spindle, T. R., Cone, E. J., et al. (2020). Pharmacodynamic dose effects of oral cannabis ingestion in healthy adults who infrequently use cannabis. Drug Alcohol Depend, 211, 107969.Google Scholar

Schoedel, K. A., Addy, C., Chakraborty, B., et al. (2012). Human abuse potential and cognitive effects of taranabant, a cannabinoid 1 receptor inverse agonist: A randomized, double-blind, placebo- and active-controlled, crossover study in recreational polydrug users. J Clin Psychopharmacol, 32, 492–502.Google Scholar

Schoedel, K. A., Chen, N., Hilliard, A., et al. (2011). A randomized, double-blind, placebo-controlled, crossover study to evaluate the subjective abuse potential and cognitive effects of nabiximols oromucosal spray in subjects with a history of recreational cannabis use. Hum Psychopharmacol Clin Exp, 26, 224–236.Google Scholar

Schoeler, T., Kambeitz, J., Behlke, I., et al. (2016). The effects of cannabis on memory function in users with and without a psychotic disorder: Findings from a combined meta-analysis. Psychol Med, 46, 177–188.Google Scholar

Scofield, M. D., Heinsbroek, J. A., Gipson, C. D., et al. (2016). The nucleus accumbens: Mechanisms of addiction across drug classes reflect the importance of glutamate homeostasis. Pharmacol Rev, 68, 816.Google Scholar

Scott, J. C., Slomiak, S. T., Jones, J. D., et al. (2018). Association of cannabis with cognitive functioning in adolescents and young adults: A systematic review and meta-analysis. JAMA Psychiatry, 75, 585–595.Google Scholar

Scott, J. C., Wolf, D. H., Calkins, M. E., et al. (2017). Cognitive functioning of adolescent and young adult cannabis users in the Philadelphia neurodevelopmental cohort. Psychol Addict Behav, 31, 423–434.Google Scholar

Sholler, D. J., Strickland, J. C., Spindle, T. R., et al. (2021). Sex differences in the acute effects of oral and vaporized cannabis among healthy adults. Addict Biol, 26, e12968.Google Scholar

Smith, J. L., De Blasio, F. M., Iredale, J. M., et al. (2017). Verbal learning and memory in cannabis and alcohol users: An event-related potential investigation. Front Psychol, 8, 2129.Google Scholar

Sneider, J. T., Gruber, S. A., Rogowska, J., et al. (2013). A preliminary study of functional brain activation among marijuana users during performance of a virtual water maze task. J Addict, 2013, 461029.Google Scholar

Solowij, N., Broyd, S., Greenwood, L.-M., et al. (2019). A randomised controlled trial of vaporised δ9-tetrahydrocannabinol and cannabidiol alone and in combination in frequent and infrequent cannabis users: Acute intoxication effects. Eur Arch Psychiatry Clin Neurosci, 269, 17–35.Google Scholar

Solowij, N., Jones, K. A., Rozman, M. E., et al. (2011). Verbal learning and memory in adolescent cannabis users, alcohol users and non-users. Psychopharmacology (Berl), 216, 131–144.Google Scholar

Solowij, N., Jones, K. A., Rozman, M. E., et al. (2012). Reflection impulsivity in adolescent cannabis users: A comparison with alcohol-using and non-substance-using adolescents. Psychopharmacology (Berl), 219, 575–586.Google Scholar

Solowij, N., and Pesa, N. (2011). Cannabis and cognition: Short- and long-term effects. In Castle, D., Murray, R., and D’Souza, D. (eds.) Marijuana and Madness (pp. 91–102). Cambridge: Cambridge University Press.Google Scholar

Spindle, T. R., Kuwabara, H., Eversole, A., et al. (2021). Brain imaging of cannabinoid type I (CB1) receptors in women with cannabis use disorder and male and female healthy controls. Addict Biol, 26, e13061.Google Scholar

Spronk, D. B., De Bruijn, E. R. A., Van Wel, J. H. P., et al. (2016). Acute effects of cocaine and cannabis on response inhibition in humans: An erp investigation. Addict Biol, 21, 1186–1198.Google Scholar

Subbaraman, M. S., and Kerr, W. C. (2021). Cannabis use frequency, route of administration, and co-use with alcohol among older adults in Washington State. J Cannabis Res, 3, 17.Google Scholar

Tait, R. J., Mackinnon, A., and Christensen, H. (2011). Cannabis use and cognitive function: 8-year trajectory in a young adult cohort. Addiction, 106, 2195–2203.Google Scholar

Takakuwa, K. M., and Schears, R. M. (2021). The emergency department care of the cannabis and synthetic cannabinoid patient: A narrative review. Int J Emerg Med, 14, 10.Google Scholar

Tamnes, C. K., Herting, M. M., Goddings, A. L., et al. (2017). Development of the cerebral cortex across adolescence: A multisample study of inter-related longitudinal changes in cortical volume, surface area, and thickness. J Neurosci, 37, 3402–3412.Google Scholar

Thames, A. D., Arbid, N., and Sayegh, P. (2014). Cannabis use and neurocognitive functioning in a non-clinical sample of users. Addict Behav, 39, 994–999.Google Scholar

Theunissen, E. L., Heckman, P., de Sousa Fernandes Perna, E. B., et al. (2015). Rivastigmine but not vardenafil reverses cannabis-induced impairment of verbal memory in healthy humans. Psychopharmacology (Berl), 232, 343–353.Google Scholar

Theunissen, E. L., Kauert, G. F., Toennes, S. W., et al. (2012). Neurophysiological functioning of occasional and heavy cannabis users during THC intoxication. Psychopharmacology (Berl), 220, 341–350.Google Scholar

United Nations Office on Drugs and Crime. (2016). World Drug Report 2016 (United Nations publication, Sales No. E.16.XI.7). New York: United Nations.Google Scholar

United Nations Office on Drugs and Crime. (2020). World Drug Report 2020 (United Nations publication, Sales No. E.20.XI.6). New York: United Nations.Google Scholar

Van Kampen, A.D., Cousijn, J., Engel, C., et al. (2020). Attentional bias, craving and cannabis use in an inpatient sample of adolescents and young adults diagnosed with cannabis use disorder: The moderating role of cognitive control. Addict Behav, 100, 106126.Google Scholar

Van Wel, J. H. P., Kuypers, K. P. C., Theunissen, E. L., et al. (2013). Single doses of THC and cocaine decrease proficiency of impulse control in heavy cannabis users. Br J Pharmacol, 170, 1410–1420.Google Scholar

Vandrey, R., Herrmann, E. S., Mitchell, J. M., et al. (2017). Pharmacokinetic profile of oral cannabis in humans: Blood and oral fluid disposition and relation to pharmacodynamic outcomes. J Anal Toxicol, 41, 83–99.Google Scholar

Vandrey, R., Stitzer, M. L., Mintzer, M. Z., et al. (2013). The dose effects of short-term dronabinol (oral THC) maintenance in daily cannabis users. Drug Alcohol Depend, 128, 64–70.Google Scholar

Volkow, N. D., Baler, R. D., Compton, W. M., et al. (2014). Adverse health effects of marijuana use. N Engl J Med, 370, 2219–2227.Google Scholar

Vujanovic, A. A., Wardle, M. C., Liu, S., et al. (2016). Attentional bias in adults with cannabis use disorders. J Addict Dis, 35, 144–153.Google Scholar

Wadsworth, E. J., Moss, S. C., Simpson, S. A., et al. (2006). Cannabis use, cognitive performance and mood in a sample of workers. J Psychopharmacol, 20, 14–23.Google Scholar

Wallace, A. L., Maple, K. E., Barr, A. T., et al. (2020). Bold responses to inhibition in cannabis-using adolescents and emerging adults after 2 weeks of monitored cannabis abstinence. Psychopharmacology (Berl), 237, 3259–3268.Google Scholar

Waris, O., Soveri, A., Ahti, M., et al. (2017). A latent factor analysis of working memory measures using large-scale data. Front Psychol, 8, 1062.Google Scholar

Wesnes, K. A., Annas, P., Edgar, C. J., et al. (2009). Nabilone produces marked impairments to cognitive function and changes in subjective state in healthy volunteers. J Psychopharmacol, 24, 1659–1669.Google Scholar

Wittemann, M., Brielmaier, J., Rubly, M., et al. (2021). Cognition and cortical thickness in heavy cannabis users. Eur Addict Res, 27, 115–122.Google Scholar

Woelfl, T., Rohleder, C., Mueller, J. K., et al. (2020). Effects of cannabidiol and delta-9-tetrahydrocannabinol on emotion, cognition, and attention: A double-blind, placebo-controlled, randomized experimental trial in healthy volunteers. Front Psychiatry, 11, 576877.Google Scholar

Wrege, J., Schmidt, A., Walter, A., et al. (2014). Effects of cannabis on impulsivity: A systematic review of neuroimaging findings. Curr Pharm Des, 20, 2126–2137.Google Scholar

Zachry, J. E., Nolan, S. O., Brady, L. J., et al. (2021). Sex differences in dopamine release regulation in the striatum. Neuropsychopharmacology, 46, 491–499.Google Scholar

Zamberletti, E., Gabaglio, M., Grilli, M., et al. (2016). Long-term hippocampal glutamate synapse and astrocyte dysfunctions underlying the altered phenotype induced by adolescent THC treatment in male rats. Pharmacol Res, 111, 459–470.Google Scholar

Zhang, M., Fung, D. S. S., and Smith, H. (2020). A literature review of attentional biases amongst individuals with substance dependency: Individual differences and modulating factors. Psychiatry Intl, 1, 125–134.CrossRefGoogle Scholar

Zhornitsky, S., Pelletier, J., Assaf, R., et al. (2021). Acute effects of partial CB(1) receptor agonists on cognition: A meta-analysis of human studies. Prog Neuropsychopharmacol Biol Psychiatry, 104, 110063.Google Scholar

Abush, H., Ghose, S., van Enkevort, E. A., et al. (2018). Associations between adolescent cannabis use and brain structure in psychosis. Psychiatry Res Neuroimaging, 276, 53–64.Google Scholar

Aguiar, D. C., Moreira, F. A., Terzian, A. L., et al. (2014). Modulation of defensive behavior by Transient Receptor Potential Vanilloid Type-1 (TRPV1) channels. Neurosci Biobehav Rev, 46, 418–428.Google Scholar

Alemany, S. (2014). Psychosis-inducing effects of cannabis are related to both childhood abuse and COMT genotypes. Acta Psychiatr Scand, 129, 54–62.Google Scholar

Antoniades, M., Schoeler, T., Radua, J., et al. (2018). Verbal learning and hippocampal dysfunction in schizophrenia: A meta-analysis. Neurosci Biobehav Rev, 86, 166–175.Google Scholar

Atakan, Z., Bhattacharyya, S., Allen, P., et al. (2013). Cannabis affects people differently: Inter-subject variation in the psychotogenic effects of D9-tetrahydrocannabinol: A functional magnetic resonance imaging study with healthy volunteers. Psychol Med, 43, 1255–1267.Google Scholar

Benetti, S., Mechelli, A., Picchioni, M., et al. (2009). Functional integration between the posterior hippocampus and prefrontal cortex is impaired in both first episode schizophrenia and the at risk mental state. Brain, 132, 2426–2436.Google Scholar

Bloomfield, M. A., Ashok, A. H., Volkow, N. D., et al. (2016). The effects of Delta(9)-tetrahydrocannabinol on the dopamine system. Nature, 539, 369–377.Google Scholar

Bloomfield, M. A., Morgan, C. J., Egerton, A., et al. (2014). Dopaminergic function in cannabis users and its relationship to cannabis-induced psychotic symptoms. Biol Psychiatry, 75, 470–478.Google Scholar

Bolo, N., Zeng, V., Clementz, B. A., et al. (2021). Hippocampal glutamate, verbal episodic memory and intrinsic neural activity in the psychosis spectrum Soc Biol Psychiatry, 89, S345.Google Scholar

Bossong, M. G., Mehta, M. A., van Berckel, B. N., et al. (2015). Further human evidence for striatal dopamine release induced by administration of 9-tetrahydrocannabinol (THC): Selectivity to limbic striatum. Psychopharmacology (Berl), 232, 2723–2729.Google Scholar

Boydell, J., Dean, K., Dutta, R., et al. (2007). A comparison of symptoms and family history in schizophrenia with and without prior cannabis use: Implications for the concept of cannabis psychosis. Schizophr Res, 93, 203–210.Google Scholar

Carr, C. P., Martins, C. M., Stingel, A. M., et al. (2013). The role of early life stress in adult psychiatric disorders: A systematic review according to childhood trauma subtypes. J Nerv Ment Dis, 201, 1007–1020.Google Scholar

Cheer, J. F., Wassum, K. M., Heien, M. L., et al. (2004). Cannabinoids enhance subsecond dopamine release in the nucleus accumbens of awake rats. J Neurosci, 24, 4393–4400.Google Scholar

Clementz, B. A., Parker, D. A., Trotti, R. L., et al. (2022). Psychosis biotypes: Replication and validation from the B-SNIP Consortium. Schizophr Bull, 48, 56–68.Google Scholar

Clementz, B. A., Sweeney, J. A., Hamm, J. P., et al. (2016). Identification of distinct psychosis biotypes using brain-based biomarkers. Am J Psychiatry, 173, 373–383.Google Scholar

Colizzi, M., Iyegbe, C., and Powell, J., et al. (2015). Interaction between DRD2 and AKT1 genetic variations on risk of psychosis in cannabis users: A case control study. NPJ Schizophren, 1, 15049.Google Scholar

Colizzi, M., Weltens, N., McGuire, P., et al. (2019). Does cannabis induce psychosis by altering glutamate signaling in the striatum? Schizophr Bull, 45, S166–S167.Google Scholar

Crane, N. A., Schuster, R. M., Fusar-Poli, P., et al. (2013). Effects of cannabis on neurocognitive functioning: Recent advances, neurodevelopmental influences, and sex differences. Neuropsychol Rev, 23, 117–137.Google Scholar

Cunha, P. J., Rosa, P. G. P., and Ayres Ade, M. (2013). Cannabis use, cognition and brain structure in first-episode psychosis. Schizophr Res, 147, 209–215.Google Scholar

D’Souza, D. C., Perry, E., MacDougall, L., et al. (2004). The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: Implications for psychosis. Neuropsychopharmacology, 29, 1558–1572.Google Scholar

Danijua, Y., Bossong, M. G., Brandt, K., et al. (2020). Do the effects of cannabis on the hippocampus and striatum increase risk for psychosis? Neurosci Biobehav Rev, 112, 324–335.Google Scholar

Dekker, N., Schmitz, N., and Peters, B. D. (2010). Cannabis use and callosal white matter structure and integrity in recent-onset schizophrenia. Psychiatry Res, 181, 51–56.Google Scholar

Di Forti, M., Quattrone, D., Freeman, T. P., et al. (2019). The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): A multicentre case-control study. Lancet Psychiatry, 6, 427–436.Google Scholar

Dow-Edwards, D., and Silva, L. (2017). Endocannabinoids in brain plasticity: Cortical maturation, HPA axis function and behavior. Brain Res, 1654, 157–164.Google Scholar

Ferraro, L., La Cascia, C., Quattrone, D., et al. (2020). Premorbid adjustment and IQ in patients with first-episode psychosis: A multisite case-control study of their relationship with cannabis use. Schizophr Bull, 46, 517–529.Google Scholar

Ferraro, L., Russo, M., O’Connor, J., et al. (2013). Cannabis users have higher premorbid IQ than other patients with first onset psychosis. Schizophr Res, 150, 129–135.Google Scholar

French, E. D. (1997) delta9-Tetrahydrocannabinol excites rat VTA dopamine neurons through activation of cannabinoid CB1 but not opioid receptors. Neurosci Lett, 226, 159–162.Google Scholar

Gage, S. H., Hickman, M., and Zammit, S. (2016). Association between cannabis and psychosis: Epidemiologic evidence. Biol Psychiatry, 79, 549–556.Google Scholar

van de Giessen, E., Weinstein, J. J., Cassidy, C. M., et al. (2017). Deficits in striatal dopamine release in cannabis dependence. Mol Psychiatry, 22, 68–75.Google Scholar

Grant, I., Gonzalez, R., Carey, C. L., et al. (2003). Non-acute (residual) neurocognitive effects of cannabis use: A meta-analytic study. J Int Neuropsychol Soc, 9, 679–689.Google Scholar

Green, M. F. (1996). What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry, 153, 321–330.Google Scholar

Guimond, S., Gu, F., Shannon, H., et al. (2021). A diagnosis and biotype comparison across the psychosis spectrum: Investigating volume and shape amygdala-hippocampal differences from the B-SNIP study. Schizophr Bull, 47, 1706–1717.Google Scholar

Haney, M., and Evins, A. E. (2016). Does cannabis cause, exacerbate or ameliorate psychiatric disorders? An oversimplified debate discussed. Neuropsychopharmacology, 41, 393–401.Google Scholar

Hanna, R. C., Shalvoy, A., Cullum, C. M., et al. (2016). Cognitive function in individuals with psychosis: Moderation by adolescent cannabis use. Schizophr Bull, 42, 1496–1503.Google Scholar

Helle, S., Gjestad, R., Johnsen, E., et al. (2013). Cognitive changes in non-affective psychosis the first 4–6 weeks after admission to a psychiatric acute ward: Effects of substance use. Schizophr Bull, 39, 262.Google Scholar

Helle, S., Gjestad, R., Johnsen, E., et al. (2014). Cognitive changes in patients with acute phase psychosis: Effects of illicit drug use. Psychiatry Res, 220, 818–824.Google Scholar

Hibar, D. P., Westlye, L. T., and van Erp, T. G. M. (2016). Subcortical volumetric abnormalities in bipolar disorder. Mol Psychiatry, 21, 1710–1716.Google Scholar

Ho, N. F., Iglesias, J. E., Sum, M. Y., et al. (2017). Progression from selective to general involvement of hippocampal subfields in schizophrenia. Mol Psychiatry, 22, 142–152.Google Scholar

Houston, J. E., Murphy, J., Shevlin, M., et al. (2011). Cannabis use and psychosis: Re-visiting the role of childhood trauma. Psychol Med, 41, 2339–2348.Google Scholar

Hu, S. S., and Mackie, K. (2015). Distribution of the endocannabinoid system in the central nervous system. Handb Exp Pharmacol, 231, 59–93.Google Scholar

Huang, J. T.-J., Leweke, F. M., Tsang, T. M., et al. (2007). CSF metabolic and proteomic profiles in patients prodromal for psychosis. PLoS ONE, 2, e756.Google Scholar

Ivleva, E. I., Clementz, B. A., and Dutcher, A. M. (2017). Brain structure biomarkers in the psychosis biotypes: Findings from the bipolar-schizophrenia network for intermediate phenotypes. Biol Psychiatry, 82, 26–39.Google Scholar

Keefe, R. S. E., Goldberg, T. E., Harvey, P. D., et al. (2004). The Brief Assessment of Cognition in Schizophrenia: Reliability, sensitivity, and comparison with a standard neurocognitive battery. Schizophr Res, 68, 283–297.Google Scholar

Kendler, K. S., Ohlsson, H., Sundquist, J., et al. (2019). Prediction of onset of substance-induced psychotic disorder and its progression to schizophrenia in a Swedish national sample. Am J Psychiatry, 176, 711–719.Google Scholar

Keshavan, M. S., Kelly, S., and Hall, M. H. (2020). The core deficit of ‘classical’ schizophrenia cuts across the psychosis spectrum. Can J Psychiatry, 65, 231–234.Google Scholar

Keshavan, M. S., Morris, D. W., Sweeney, J. A., et al. (2011). A dimensional approach to the psychosis spectrum between bipolar disorder and schizophrenia: The Schizo-Bipolar Scale. Schizophr Res, 133, 250–254.Google Scholar

Koenders, L., Machielsen, M. W. J., and van der Meer, F. J. (2015). Brain volume in male patients with recent onset schizophrenia with and without cannabis use disorders. J Psychiatry Neurosci, 40, 197–206.Google Scholar

Koethe, D., Giuffrida, A., Schreiber, D., et al. (2009). Anandamide elevation in cerebrospinal fluid in initial prodromal states of psychosis. Br J Psychiatry, 194, 371–372.Google Scholar

Kraguljac, N. V., Karper, L. P., Seibyl, J. P., et al. (2017). Ketamine modulates hippocampal neurochemistry and functional connectivity: A combined magnetic resonance spectroscopy and resting-state fMRI study in healthy volunteers. Mol Psychiatry, 22, 562–569.Google Scholar

Krystal, J. H., Karper, L. P., Seibyl, J. P., et al. (1994). Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry, 51, 199–214.Google Scholar

Ksir, C., and Hart, C. L. (2016). Correlation still does not imply causation. Lancet Psychiatry, 3, 401.Google Scholar

Lee, T. T., Hill, M. N., and Lee, F. S. (2016). Developmental regulation of fear learning and anxiety behavior by endocannabinoids. Genes Brain Behav, 15, 108–124.Google Scholar

Leweke, F. M., Piomelli, D., Pahlisch, F., et al. (2012). Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry, 2, e94.Google Scholar

Lieberman, J. A., Girgis, R. R., Brucato, G., et al. (2018). Hippocampal dysfunction in the pathphysiology of schizophrenia: A selective review and hypothesis for early detection and intervention. Mol Psychiatry, 23, 1764–1772.Google Scholar

Loberg, E.-M., Helle, S., Nygard, M., et al. (2014). The cannabis pathway to non-affective psychosis may reflect less neurobiological vulnerability. Front Psychiatry, 5, 159.Google Scholar

Lubman, D. I., Cheetham, A., and Yucel, M. (2015). Cannabis and adolescent brain development. Pharmacol Ther, 148, 1–16.Google Scholar

Makowski, C., Bodnar, M., Shenker, J. J., et al. (2017). Linking persistent negative symptoms to amygdala-hippocampus structure in first-episode psychosis. Transl Psychiatry, 7, e1195.Google Scholar

Malchow, B., Hasan, A., Schneider-Axmann, T., et al. (2013). Effects of cannabis and familial loading on subcortical brain volumes in first-episode schizophrenia. Eur Arch Psychiatry Clin Neurosci, 263, S155–S168.Google Scholar

Mallet, J., Ramoz, N., Le Strat, Y., et al. (2017). Heavy cannabis use prior psychosis in schizophrenia: Clinical, cognitive and neurological evidences for a new endophenotype? Eur Arch Psychiatry Clin Neurosci, 267, 629–638.Google Scholar

Meyer, H. C., Lee, F. S., and Gee, D. G. (2018). The role of the endocannabinoid system and genetic variation in adolescent brain development. Neuropsychopharmacology, 43, 21–33.Google Scholar

Moghaddam, B., and Javitt, D. (2012). From revolution to evolution: The glutamate hypothesis of schizophrenia and its implication for treatment. Neuropsychopharmacology, 37, 4–15.Google Scholar

Morrison, P. D., Zois, V., McKeown, D. A., et al. (2009). The acute effects of synthetic intravenous Delta9-tetrahydrocannabinol on psychosis, mood and cognitive functioning. Psychol Med, 39, 1607–1616.Google Scholar

O’Neill, A., Annibale, L., Blest-Hopley, G., et al. (2021). Cannabidiol modulation of hippocampal glutamate in early psychosis. J Psychopharmacol, 35, 814–822.Google Scholar

Paul, S., and Bhattacharyya, S. (2021). Cannabis use-related working memory deficit mediated by lower left hippocampal volume. Addict Biol, 26, e12984.Google Scholar

Quattrone, D., Ferraro, L., Tripoli, G., et al. (2020). The Relation of the Psychosis Continuum with Schizophrenia Polygenic Risk Score and Cannabis Use. Schizophrenia International Research Society.Google Scholar

Rabin, R. A., Zakzanis, K. K., and George, T. P. (2011). The effects of cannabis use on neurocognition in schizophrenia: A meta-analysis. Schizophr Res, 128, 111–116.Google Scholar

Ranganathan, M., and D’Souza, D. C. (2006). The acute effects of cannabinoids on memory in humans: A review. Psychopharmacologia, 188, 425–444.Google Scholar

Rasetti, R., Sambataro, F., Chen, Q., et al. (2011). Altered cortical network dynamics: A potential intermediate phenotype for schizophrenia and association with ZNF804A. Arch Gen Psychiatry, 68, 1207–1217.Google Scholar

Raver, S. M., Haughwout, S. P., and Keller, A. (2013). Adolescent cannabinoid exposure permanently suppresses cortical oscillations in adult mice. Neuropsychopharmacology, 38, 2338–2347.Google Scholar

del Re, E. C., Yassine, W., Zeng, V., et al. (2022). Childhood trauma and cannabis interactions in affecting psychosis onset: Role of the anterior–posterior axis of the hippocampus and differences in cannabis use before or after psychosis onset. medRxiv.Google Scholar

Realini, N., Rubino, T., and Parolaro, D. (2009). Neurobiological alterations at adult age triggered by adolescent exposure to cannabinoids. Pharmacol Res, 60, 132–138.Google Scholar

Renard, J., Krebs, M. O., Le Pen, G., et al. (2014). Long-term consequences of adolescent cannabinoid exposure in adult psychopathology. Front Neurosci, 8, 361.Google Scholar

Rentzsch, J., Stadtmann, A., Montag, C., et al. (2016). Attentional dysfunction in abstinent long-term cannabis users with and without schizophrenia. Eur Arch Psychiatry Clin Neurosci, 266, 409–421.Google Scholar

Rigucci, S., Xin, L., Klauser, P., et al. (2017). Cannabis use in early psychosis is associated with reduced glutamate levels in the prefrontal cortex. Psychopharmacologia, 235, 13–22.Google Scholar

Rubino, T., and Parolaro, D. (2008). Long lasting consequences of cannabis exposure in adolescence. Mol Cell Endocrinol, 286, S108–S113.Google Scholar

Rubino, T., and Parolaro, D. (2016). The impact of exposure to cannabinoids in adolescence: Insights from animal models. Biol Psychiatry, 79, 578–585.Google Scholar

Rubino, T., Prini, P., Piscitelli, F., et al. (2015). Adolescent exposure to THC in female rats disrupts developmental changes in the prefrontal cortex. Neurobiol Dis, 226, 159–162.Google Scholar

Sami, M. B., Annibale, L., O’Neill, A., et al. (2021). Eye movements in patients in early psychosis with and without a history of cannabis use. NPJ Schizophrenia, 7, 1–7.Google Scholar

Sami, M. B., and Bhattacharyya, S. (2018). Are cannabis-using and non-using patients different groups? Towards understanding the neurobiology of cannabis use in psychotic disorders. J Psychopharmacol, 32, 825–849.Google Scholar

Sami, M. B., Worker, A., Colizzi, M., et al. (2020). Association of cannabis with glutamatergic levels in patients with early psychosis: Evidence for altered volume striatal glutamate relationships in patients with a history of cannabis use in early psychosis. Transl Psychiatry, 10, 111.Google Scholar

Scheffler, F., Plessis, S. D., Asmal, L., et al. (2021). Cannabis use and hippocampal subfield volumes in males with a first episode of a schizophrenia spectrum disorder and healthy controls. Schizophr Res, 231, 13–21.Google Scholar

Schneider, M. (2008). Puberty as a highly vulnerable developmental period for the consequences of cannabis exposure. Addict Biol, 13, 253–263.Google Scholar

Schnell, T., Kleiman, A., Gouzoulis-Mayfrank, E., et al. (2012). Increased gray matter density in patients with schizophrenia and cannabis use: A voxel-based morphometric study using DARTEL. Schizophr Res, 138, 183–187.Google Scholar

Schoeler, T., Kambeitz, J., and Bhattacharyya, S. (2015) The effect of cannabis on memory function in users with and without a psychotic disorder: A meta-analysis. Psychol Med, 10, 1–12.Google Scholar

Shakory, S., Watts, J. J., Hafizi, S., et al. (2018). Hippocampal glutamate metabolites and glial activation in clinical high risk and first episode psychosis. Neuropsychopharmacology, 43, 2249–2255.Google Scholar

Smith, M. J., Cobia, D. J., Reilly, J. L., et al. (2015). Cannabis-related episodic memory deficits and hippocampal morphological differences in healthy individuals and schizophrenia subjects. Hippocampus, 25, 1042–1051.Google Scholar

Solowij, N., Malterfang, M., Lubman, D. I., et al. (2013). Alteration to hippocampal shape in cannabis users with and without schizophrenia. Schizophr Res, 143, 179–184.Google Scholar

Stip, E. (2006). Cognition, schizophrenia and the effect of antipsychotics. Encephale, 32, 341–350.Google Scholar

Stirling, J., Lewis, S., and Hopkins, R., et al. (2005). Cannabis use prior to first onset psychosis predicts spared neurocognition at 10-year follow-up. Schizophr Res, 75, 135–137.Google Scholar

Stokes, P. R., Egerton, A., Watson, B., et al. (2012). History of cannabis use is not associated with alterations in striatal dopamine D2/D3 receptor availability. J Psychopharmacol, 26, 144–149.Google Scholar